TY - JOUR
T1 - Outcomes of induction chemotherapy for head and neck cancer patients a combined study of two national cohorts in Taiwan
AU - Chen, Jin-Hua
AU - Yen, Yu-Chun
AU - Liu, Shing Hwa
AU - Yuan, Sheng Po
AU - Wu, Li Li
AU - Lee, Fei-Peng
AU - Lin, Kuan Chou
AU - Lai, Ming-Tang
AU - Wu, Chia-Che
AU - Chen, Tsung Ming
AU - Chang, Chia Lun
AU - Chow, Jyh-Ming
AU - Ding, Yi Fang
AU - Lin, Ming-Chin
AU - Wu, Szu-Yuan
N1 - Export Date: 29 March 2016
CODEN: MEDIA
通訊地址: Wu, S.-Y.; Institute of Toxicology, College of Medicine, National Taiwan UniversityTaiwan; 電子郵件： [email protected]
參考文獻: Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013 (2013) CA Cancer J Clin., 63, pp. 11-30; (2011) Health Promotion Administration MoHaW: Taiwan Cancer Registry Report, 2011 Edition, , Health Promotion Administration, Ministry of Health and Welfare; Pointreau, Y., Garaud, P., Chapet, S., Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation (2009) J Natl Cancer Inst., 101, pp. 498-506; Pignon, J.P., Le Maitre, A., Maillard, E., Meta-analysis of chemotherapy in head and neck cancer (Mach-NC): An update on 93 randomised trials and 17, 346 patients (2009) Radiother Oncol., 92, pp. 4-14; Posner, M.R., Hershock, D.M., Blajman, C.R., Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer (2007) N Engl J Med., 357, pp. 1705-1715; Vermorken, J.B., Remenar, E., Van Herpen, C., Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (2007) N Engl J Med., 357, pp. 1695-1704; Haddad, R., O'Neill, A., Rabinowits, G., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemora-diotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial (2013) Lancet Oncol., 14, pp. 257-264; Cohen, E.E., Karrison, T.G., Kocherginsky, M., Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer (2014) J Clin Oncol., 32, pp. 2735-2743; Charlson, M., Szatrowski, T.P., Peterson, J., Validation of a combined comorbidity index (1994) J Clin Epidemiol., 47, pp. 1245-1251; Chow, S., Wang, H., Shao, J., (2008) Sample Size Calculations in Clinical Research. 2nd Ed, p. 177. , New York: Chapman and Hall/CRC; Forastiere, A.A., Goepfert, H., Maor, M., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer (2003) N Engl J Med., 349, pp. 2091-2098; Adelstein, D.J., Li, Y., Adams, G.L., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squa-mous cell head and neck cancer (2003) J Clin Oncol., 21, pp. 92-98; Calais, G., Alfonsi, M., Bardet, E., Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma (1999) J Natl Cancer Inst., 91, pp. 2081-2086; Domenge, C., Hill, C., Lefebvre, J.L., Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC) (2000) Br J Cancer., 83, pp. 1594-1598; Zorat, P.L., Paccagnella, A., Cavaniglia, G., Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up (2004) J Natl Cancer Inst., 96, pp. 1714-1717; Paccagnella, A., Orlando, A., Marchiori, C., Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo (1994) J Natl Cancer Inst., 86, pp. 265-272; Pignon, J.P., Bourhis, J., Domenge, C., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Mach-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer (2000) Lancet., 355, pp. 949-955; Hitt, R., Grau, J.J., Lopez-Pousa, A., A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer (2014) Ann Oncol., 25, pp. 216-225; Takacsi-Nagy, Z., Hitre, E., Remenar, E., Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiother-apy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study (2015) Strahlenther Onkol., 191, pp. 635-641; Paccagnella, A., Ghi, M.G., Loreggian, L., Concomitant chemor-adiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study (2010) Ann Oncol., 21, pp. 1515-1522; Posner, M.R., Lorch, J.H., Goloubeva, O., Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial (2011) Ann Oncol., 22, pp. 1071-1077; Liao, C.T., Wallace, C.G., Lee, L.Y., Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area (2014) Oral Oncol., 50, pp. 721-731; Liao, C.T., Kang, C.J., Chang, J.T., Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area (2007) Oral Oncol., 43, pp. 811-819; Corry, J., Peters, L., Kleid, S., Larynx preservation for patients with locally advanced laryngeal cancer (2013) J Clin Oncol., 31, pp. 840-844; Balermpas, P., Bauer, C., Fraunholz, I., Concomitant chemora-diotherapy versus induction chemotherapy followed by chemora-diotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis (2014) Strahlenther Onkol., 190, pp. 256-262; Lefebvre, J.L., Pointreau, Y., Rolland, F., Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study (2013) J Clin Oncol., 31, pp. 853-859; Faivre, S., Albert, S., Raymond, E., Induction chemotherapy challenges for head and neck cancer (2013) Lancet Oncol., 14, pp. 188-189
PY - 2016
Y1 - 2016
N2 - The use of induction chemotherapy (CT) is controversial. We compared the survival of head and neck cancer patients receiving docetaxel-or platinum-based induction CT before concomitant chemoradiotherapy (CCRT) with the survival of those receiving upfront CCRT alone. Data fromtheNationalHealth Insurance and cancer registry databases in Taiwan were linked and analyzed. We enrolled patients who had head and neck cancer between January 1, 2002andDecember 31, 2011. Followup was from the index date to December 31, 2013.We included head and neck patients diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9 who were aged
AB - The use of induction chemotherapy (CT) is controversial. We compared the survival of head and neck cancer patients receiving docetaxel-or platinum-based induction CT before concomitant chemoradiotherapy (CCRT) with the survival of those receiving upfront CCRT alone. Data fromtheNationalHealth Insurance and cancer registry databases in Taiwan were linked and analyzed. We enrolled patients who had head and neck cancer between January 1, 2002andDecember 31, 2011. Followup was from the index date to December 31, 2013.We included head and neck patients diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes 140.0-148.9 who were aged
U2 - 10.1097/MD.0000000000002845
DO - 10.1097/MD.0000000000002845
M3 - Article
C2 - 26886647
SN - 0025-7974
VL - 95
SP - e2845
JO - Medicine (United States)
JF - Medicine (United States)
IS - 7
ER -
